{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:56:37Z","timestamp":1793858197540,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["17411965100"],"award-info":[{"award-number":["17411965100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671589, 81871272"],"award-info":[{"award-number":["81671589, 81871272"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801602"],"award-info":[{"award-number":["81801602"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite expansion in the 2006 Sydney antiphospholipid syndrome (APS) classification criteria to include IgG\/IgM anti-\u03b22-glycoprotein (a\u03b22GPI) antibodies in addition to IgG\/IgM anti-cardiolipin antibodies (aCL) and lupus anticoagulant (LAC), some individuals with clinical features of APS remain seronegative (seronegative APS or SNAPS) and are at risk of recurrent thrombosis and pregnancy morbidities. Our aim was to assess the value of \u201cnon-criteria\u201d aPL antibodies to detect these SNAPS patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred ninety-two APS patients, 90 SNAPS patients, 193 autoimmune disease controls, and 120 healthy controls were evaluated. Ten antiphospholipid antibodies (aPLs) were tested using commercial kits, including 5 non-criteria aPLs: anti-phosphatidylserine\/prothrombin antibodies (aPS\/PT) IgG\/IgM, aCL IgA, a\u03b22GPI IgA, and anti-\u03b22GPI Domain 1 (a\u03b22GPI-D1) IgG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Up to 60.9% of the SNAPS and 93.5% of APS patients were detected by at least one non-criteria aPL. aPS\/PT IgG had the highest Youden index in classifying APS and SNAPS from controls. aPS\/PT IgG and a\u03b22GPI Domain 1 IgG seem to be the most significant risk factors for thrombotic events and pregnancy morbidity, respectively. aPS\/PT IgG\/IgM and a\u03b22GPI-D1 IgG were detected in some SNAPS patients, while IgA isotypes of aCL\/a\u03b22GPI tended to appear together with other biomarkers. The combined analysis showed enhanced diagnostic performance with the inclusion of non-criteria aPLs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Recognition of SNAPS patients is critical for clinical management and prevention of potential thrombotic and obstetric adverse events. The non-criteria antiphospholipid antibodies help to identify a considerable portion (60.9%) of these patients who otherwise may remain untreated and at clinical risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-2131-4","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T14:03:43Z","timestamp":1582293823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["\u201cNon-criteria\u201d antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort"],"prefix":"10.1186","volume":"22","author":[{"given":"Tingting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junna","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"issue":"6399","key":"2131_CR1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","volume":"287","author":"GR Hughes","year":"1983","unstructured":"Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed). 1983;287(6399):1088\u20139.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"7","key":"2131_CR2","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T, Lockshin MD, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol. 1999;42(7):1309\u201311.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2131_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemostasis"},{"issue":"12","key":"2131_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/ard.2003.006163","volume":"62","author":"GR Hughes","year":"2003","unstructured":"Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003;62(12):1127.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2131_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/annrheumdis-2011-200614","volume":"71","author":"JL Rodriguez-Garcia","year":"2012","unstructured":"Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called \u2018seronegative APS\u2019). Ann Rheum Dis. 2012;71(2):242\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2131_CR6","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s10067-006-0487-8","volume":"26","author":"I Lazurova","year":"2007","unstructured":"Lazurova I, Macejova Z, Tomkova Z, Remenar F, Boor A, Lazur J, et al. Severe limb necrosis: primary thrombotic microangiopathy or \u201cseronegative\u201d catastrophic antiphospholipid syndrome? A diagnostic dilemma. Clin Rheumatol. 2007;26(10):1737\u201340.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"2131_CR7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.revmed.2014.04.012","volume":"35","author":"F Joalland","year":"2014","unstructured":"Joalland F, de Boysson H, Darnige L, Johnson A, Jeanjean C, Cheze S, et al. Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report. Rev Med Interne. 2014;35(11):752\u20136.","journal-title":"Rev Med Interne"},{"issue":"3","key":"2131_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jemermed.2014.06.031","volume":"48","author":"LI Losonczy","year":"2015","unstructured":"Losonczy LI, Johnson B, Sidhu J, Li J, Feeney CM. Seronegative catastrophic antiphospholipid syndrome in a young female presenting with a headache. J Emerg Med. 2015;48(3):294\u20137.","journal-title":"J Emerg Med"},{"issue":"8","key":"2131_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/ket126","volume":"52","author":"R Nayfe","year":"2013","unstructured":"Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford). 2013;52(8):1358\u201367.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2131_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1160\/TH13-06-0509","volume":"111","author":"S Sciascia","year":"2014","unstructured":"Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354\u201364.","journal-title":"Thromb Haemost"},{"issue":"6","key":"2131_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1515\/cclm-2016-0638","volume":"55","author":"A Hoxha","year":"2017","unstructured":"Hoxha A, Mattia E, Tonello M, Grava C, Pengo V, Ruffatti A. Antiphosphatidylserine\/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med. 2017;55(6):890\u20138.","journal-title":"Clin Chem Lab Med"},{"issue":"2\u20133","key":"2131_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12026-013-8421-z","volume":"56","author":"F Pregnolato","year":"2013","unstructured":"Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A, et al. Anti-phosphatidylserine\/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. 2013;56(2\u20133):432\u20138.","journal-title":"Immunol Res"},{"key":"2131_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fimmu.2019.00376","volume":"10","author":"S Sciascia","year":"2019","unstructured":"Sciascia S, Radin M, Cecchi I, Rubini E, Scotta A, Rolla R, et al. Reliability of lupus anticoagulant and anti-phosphatidylserine\/prothrombin autoantibodies in antiphospholipid syndrome: a multicenter study. Front Immunol. 2019;10:376.","journal-title":"Front Immunol"},{"issue":"4","key":"2131_CR14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1515\/cclm-2017-0502","volume":"56","author":"H Shi","year":"2018","unstructured":"Shi H, Zheng H, Yin YF, Hu QY, Teng JL, Sun Y, et al. Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(4):614\u201324.","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"2131_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0961203314541317","volume":"23","author":"S Sciascia","year":"2014","unstructured":"Sciascia S, Bertolaccini ML. Thrombotic risk assessment in APS: the Global APS Score (GAPSS). Lupus. 2014;23(12):1286\u20137.","journal-title":"Lupus."},{"issue":"1","key":"2131_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-2836(02)00621-6","volume":"321","author":"M Hammel","year":"2002","unstructured":"Hammel M, Kriechbaum M, Gries A, Kostner GM, Laggner P, Prassl R. Solution structure of human and bovine beta (2)-glycoprotein I revealed by small-angle X-ray scattering. J Mol Biol. 2002;321(1):85\u201397.","journal-title":"J Mol Biol"},{"issue":"8","key":"2131_CR17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","volume":"116","author":"C Agar","year":"2010","unstructured":"Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116(8):1336\u201343.","journal-title":"Blood."},{"key":"2131_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaut.2019.02.002","volume":"99","author":"A Shemer","year":"2019","unstructured":"Shemer A, Willis R, Gonzalez EB, Romay-Penabad Z, Shovman O, Shoenfeld Y, et al. Oral administration of domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome. J Autoimmun. 2019;99:98\u2013103.","journal-title":"J Autoimmun"},{"issue":"8","key":"2131_CR19","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/art.39187","volume":"67","author":"L Andreoli","year":"2015","unstructured":"Andreoli L, Chighizola CB, Nalli C, Gerosa M, Borghi MO, Pregnolato F, et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2 -glycoprotein i domain 1 and domain 4\/5: ratio of anti-domain 1 to anti-domain 4\/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumat (Hoboken). 2015;67(8):2196\u2013204.","journal-title":"Arthritis Rheumat (Hoboken)"},{"issue":"2","key":"2131_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/0961203317738227","volume":"27","author":"D Perez","year":"2018","unstructured":"Perez D, Tincani A, Serrano M, Shoenfeld Y, Serrano A. Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess. Lupus. 2018;27(2):177\u20138.","journal-title":"Lupus."},{"issue":"1","key":"2131_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.33349","volume":"64","author":"G Lakos","year":"2012","unstructured":"Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64(1):1\u201310.","journal-title":"Arthritis Rheum"},{"key":"2131_CR22","doi-asserted-by":"publisher","first-page":"704395","DOI":"10.1155\/2014\/704395","volume":"2014","author":"R Ruiz-Garcia","year":"2014","unstructured":"Ruiz-Garcia R, Serrano M, Martinez-Flores JA, Mora S, Morillas L, Martin-Mola MA, et al. Isolated IgA anti- beta2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res. 2014;2014:704395.","journal-title":"J Immunol Res"},{"issue":"11","key":"2131_CR23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/jth.12722","volume":"12","author":"DR Arachchillage","year":"2014","unstructured":"Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemostasis. 2014;12(11):1801\u20139.","journal-title":"J Thromb Haemostasis"},{"issue":"8","key":"2131_CR24","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1182\/blood.V83.8.2383b.2383b","volume":"83","author":"M Sorice","year":"1994","unstructured":"Sorice M, Griggi T, Circella A, Lenti L, Arcieri P, Domenico di Nucci G, et al. Protein S antibodies in acquired protein S deficiencies. Blood. 1994;83(8):2383\u20134.","journal-title":"Blood."},{"issue":"16","key":"2131_CR25","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2010-04-279208","volume":"116","author":"E Ortona","year":"2010","unstructured":"Ortona E, Capozzi A, Colasanti T, Conti F, Alessandri C, Longo A, et al. Vimentin\/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood. 2010;116(16):2960\u20137.","journal-title":"Blood."},{"issue":"4","key":"2131_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1055\/s-0037-1613073","volume":"87","author":"M Sorice","year":"2002","unstructured":"Sorice M, Ferro D, Misasi R, Pittoni V, Longo A, Circella A, et al. Evidence for anticoagulant activity and beta2-GPI accumulation in late endosomes of endothelial cells induced by anti-LBPA antibodies. Thromb Haemost. 2002;87(4):735\u201341.","journal-title":"Thromb Haemost"},{"key":"2131_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/978-1-4939-0326-9_8","volume":"1134","author":"F Conti","year":"2014","unstructured":"Conti F, Alessandri C, Spinelli FR, Capozzi A, Martinelli F, Recalchi S, et al. TLC immunostaining for detection of \u201cantiphospholipid\u201d antibodies. Methods Mol Biol (Clifton). 2014;1134:95\u2013101.","journal-title":"Methods Mol Biol (Clifton)"},{"issue":"6","key":"2131_CR28","doi-asserted-by":"publisher","first-page":"R180","DOI":"10.1186\/ar2091","volume":"8","author":"C Alessandri","year":"2006","unstructured":"Alessandri C, Sorice M, Bombardieri M, Conigliaro P, Longo A, Garofalo T, et al. Antiphospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res Ther. 2006;8(6):R180.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2131_CR29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1046\/j.1365-2249.1999.01064.x","volume":"118","author":"RR Forastiero","year":"1999","unstructured":"Forastiero RR, Martinuzzo ME, Carreras LO. Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot. Clin Exp Immunol. 1999;118(3):480\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"2131_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.thromres.2011.04.004","volume":"128","author":"L Persijn","year":"2011","unstructured":"Persijn L, Decavele AS, Schouwers S, Devreese K. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res. 2011;128(6):565\u20139.","journal-title":"Thromb Res"},{"issue":"5","key":"2131_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","volume":"14","author":"MM Abreu","year":"2015","unstructured":"Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, et al. The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401\u201314.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2131_CR32","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2131_CR33","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2131_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2131_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2131_CR36","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2131_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.autrev.2012.08.002","volume":"12","author":"H Meijide","year":"2013","unstructured":"Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML. The clinical relevance of IgA anticardiolipin and IgA anti-beta2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev. 2013;12(3):421\u20135.","journal-title":"Autoimmun Rev"},{"issue":"24","key":"2131_CR38","doi-asserted-by":"publisher","first-page":"12093","DOI":"10.1021\/ac403194t","volume":"85","author":"JA Martinez-Flores","year":"2013","unstructured":"Martinez-Flores JA, Serrano M, Alfaro J, Mora S, Paz-Artal E, Morales JM, et al. Heterogeneity between diagnostic tests for IgA anti-beta2 glycoprotein I: explaining the controversy in studies of association with vascular pathology. Anal Chem. 2013;85(24):12093\u20138.","journal-title":"Anal Chem"},{"key":"2131_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","volume":"90","author":"CB Chighizola","year":"2018","unstructured":"Chighizola CB, Pregnolato F, Andreoli L, Bodio C, Cesana L, Comerio C, et al. Beyond thrombosis: anti-beta2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J Autoimmun. 2018;90:76\u201383.","journal-title":"J Autoimmun"},{"issue":"11","key":"2131_CR40","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3899\/jrheum.170044","volume":"44","author":"N Zohoury","year":"2017","unstructured":"Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, Shums Z, Ateka-Barrutia O, Sorice M, et al. Closing the serological gap in the antiphospholipid syndrome: the value of \u201cnon-criteria\u201d antiphospholipid antibodies. J Rheumatol. 2017;44(11):1597\u2013602.","journal-title":"J Rheumatol"},{"key":"2131_CR41","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.3389\/fimmu.2018.02971","volume":"9","author":"E Litvinova","year":"2018","unstructured":"Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018;9:2971.","journal-title":"Front Immunol"},{"issue":"3","key":"2131_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/096120339700600314","volume":"6","author":"L Seisdedos","year":"1997","unstructured":"Seisdedos L, Munoz-Rodriguez FJ, Cervera R, Font J, Ingelmo M. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus. 1997;6(3):285\u20136.","journal-title":"Lupus."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2131-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-2131-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-2131-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T01:07:11Z","timestamp":1613869631000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-2131-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-2131-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research was performed according to the Declaration of Helsinki and approved by the Institutional Review Broad of Ruijin Hospital (ID: 2016-62), Shanghai Jiaotong University School of Medicine, Shanghai, China. Informed consent was obtained from all individuals included in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Gary L. Norman is an employee of Inova Diagnostics, and Jinfeng Zhou is an employee of Werfen China. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The remaining authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}